|
Volumn 170, Issue 2, 2017, Pages 222-
|
IL-4Rα Inhibitor for Atopic Disease
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CORTICOSTEROID;
DUPILUMAB;
INTERLEUKIN 13 RECEPTOR;
INTERLEUKIN 4 RECEPTOR;
INTERLEUKIN 4 RECEPTOR ALPHA;
IL4R PROTEIN, HUMAN;
MONOCLONAL ANTIBODY;
ANTIINFLAMMATORY ACTIVITY;
ASTHMA;
ATOPIC DERMATITIS;
ATOPY;
B LYMPHOCYTE;
BASOPHIL;
CLINICAL STUDY;
CLINICAL TRIAL (TOPIC);
DENDRITIC CELL;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG INDICATION;
DRUG SAFETY;
DRUG TARGETING;
EOSINOPHILIC ESOPHAGITIS;
EPITHELIUM CELL;
FIBROBLAST;
FOOD ALLERGY;
HUMAN;
MAST CELL;
NOSE POLYP;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PREVALENCE;
PRIORITY JOURNAL;
SHORT SURVEY;
T LYMPHOCYTE;
UNITED STATES;
ANTAGONISTS AND INHIBITORS;
DERMATITIS, ATOPIC;
MOLECULARLY TARGETED THERAPY;
ANTIBODIES, MONOCLONAL;
CLINICAL TRIALS AS TOPIC;
DERMATITIS, ATOPIC;
DRUG APPROVAL;
HUMANS;
INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT;
MOLECULAR TARGETED THERAPY;
|
EID: 85023618354
PISSN: 00928674
EISSN: 10974172
Source Type: Journal
DOI: 10.1016/j.cell.2017.06.046 Document Type: Short Survey |
Times cited : (33)
|
References (10)
|